Insider Brief: EndoQuest Robotics Secures Series D-2 Funding to Advance Revolutionary Endoluminal Surgical Platform

EndoQuest Robotics has successfully closed a Series D-2 funding round, co-led by Crescent Enterprises and Dr. Fred Moll, aimed at propelling its endoluminal surgical technology and supporting critical clinical trials toward U.S. FDA clearance.

The financing will expedite EndoQuest’s pivotal PARADIGM trial, early feasibility studies for upper GI procedures, and the development of cutting-edge endoluminal visualization technologies. With strong backing and initial clinical success in colorectal procedures, EndoQuest is strategically positioning its flexible robotic system to serve underserved surgical markets and potentially transform robotic endoscopic surgery.

Insider Brief: Advancing Robotic Surgery with EndoQuest Robotics

In a notable step forward for the field of robotic surgery, EndoQuest Robotics has successfully closed a Series D-2 funding round, co-led by Crescent Enterprises and esteemed surgeon Dr. Fred Moll. This investment is poised to accelerate the development of their innovative endoluminal surgical platform and bolster ongoing clinical trials aimed at achieving U.S. FDA clearance.

A Game-Changing Funding Round

The recent funding will significantly propel EndoQuest’s pivotal PARADIGM trial and enhance early feasibility studies focused on upper gastrointestinal (GI) procedures. Additionally, it aims to advance the company’s cutting-edge endoluminal visualization technologies, which are set to transform the landscape of robotic endoscopic surgery.

Dr. Moll, a pioneer in robotic surgery, lauded EndoQuest’s capabilities, stating, “EndoQuest has developed a groundbreaking capability that could revolutionize how procedures are performed in robotic endoscopic surgery.” His confidence is bolstered by his observations of the company’s initial clinical successes, which have showcased the system’s innovative features.

Strategic Backing

Neeraj Agrawal, Executive Director of Crescent Enterprises and a director at EndoQuest, reinforced the strategic merit of the investment. He noted, “EndoQuest perfectly fits our investment thesis of targeting high-CAGR surgical robotics fields.” With a focus on surgical theaters that lack competitive incumbents, EndoQuest’s platform is uniquely positioned to capture value across various medical contexts. The growing interest from strategic partners further validates their approach and vision.

Interim CEO Eduardo Fonseca emphasized the company’s commitment to four fundamental pillars of value: strong clinical data from trials, a clear pathway to FDA clearance, cutting-edge visualization systems, and the development of new upper GI clinical procedures alongside their ongoing IDE trial. He stated, “Through focused execution across these four pillars, we are working to bring the impact of our pioneering technology to patients and physicians worldwide.”

Chief Financial Officer Nicholas Drysdale echoed this sentiment by emphasizing the company’s proactive stance on capital discipline, which aims to deliver long-term returns for investors while expanding their technology portfolio.

The Exciting PARADIGM Trial

A highlight of EndoQuest’s recent achievements is the PARADIGM Trial (Prospective Assessment of a Robotic Assisted Device in Gastrointestinal Medicine). This study recently reached its first clinical milestone with two successful colorectal endoscopic submucosal dissection (ESD) procedures performed by Dr. Eric Haas at HCA Houston Healthcare Medical Center. The procedures targeted complex colorectal lesions, illustrating the Endoluminal Surgical (ELS) System’s potential to treat conditions that traditionally require invasive surgeries.

Set to enroll 50 patients across five leading U.S. hospitals, including renowned facilities like Brigham and Women’s Hospital and Mayo Clinic, the trial aims to evaluate the safety and effectiveness of the ELS System. Following the successful completion of this study, EndoQuest plans to pursue market authorization for the ELS System in the United States.

Looking Ahead

With the backing of notable investors including Puma Venture Capital and The University of Texas Health Science Center at Houston, EndoQuest Robotics is on a trajectory to reshape the surgical landscape. The ambitious goals and advanced technology underscore the company’s commitment to improving surgical care through innovative solutions.

In conclusion, as EndoQuest accelerates its clinical programs and technological advancements, the next few years could bring transformative change to robotic endoscopic surgery, promising enhanced patient outcomes and a shift in standard surgical practices. The future of minimally invasive surgeries appears to be bright, thanks to the pioneering work at EndoQuest Robotics.